CytoSPAR is a bio-molecular engineering company. CytoSPAR is currently developing and commercializing the proprietary Surface Programmable Activation Receptor (SPAR™) diagnostic and therapeutic platform designed to detect deadly viruses and bacteria.The company's platform is a cell-based targeting system that is highly sensitive and provides results in less than 10 minutes, enabling doctors to detect deadly viruses at comparably low costs.